This was the stock's third consecutive day of losses.

Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc.

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.